Skip to main content
Brian Yang on Muck Rack

Brian Yang

Verified
  • Contributing Writer, STAT
Beijing
As seen in: STAT, LinkedIn, Wiley Online Library, Substack, Taylor & Francis Online, Flipboard, Patch, The Boston Globe, EIN News, Lexology, EIN Presswire and
contributing writer @statnews cover China biotech for over a decade
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Brian

Contact Brian, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The Death of an Economist: How Gao Shanwen’s 18-month Ordeal Exposes China Cell Therapy’s Overlooked Gap

|
By Brian Yang Verified
| Substack
Capition: Gao Shanwen died at 55, after 18-month battle with lymphoma. AI-generated Gao, a well-known macroeconomist’s passing, after a short one year and a half battle with a rare cancer, sparks wide debate about cell therapy development and clinical use in China, the country with the largest cell therapy development pipeline in the world. Gao’s illness unfolded over nearly eighteen months, crossing multiple hospitals in Beijing, Hong Kong, and finally back to Beijing.
Open in Who Shared Issue with article?

After 20 Years Covering Biotech, Why I Wrote About Chinese and Chinese American Scientists

|
By Brian Yang Verified
| LinkedIn
When Xiuli Wang stood at a podium at Peking University one day in 2018, she was full of hope for a promising therapy, CAR-T cell therapy to treat one of the most fatal blood cancers, lymphoma. Wang was a research professor and director of hematology and hematopoietic cell transplantation at City of Hope, in Los Angeles.
Open in Who Shared Issue with article?

The U.S.-China biotech crackdown may hurt the scientists America needs the most

|
By Brian Yang Verified
| EIN News
By Brian Yang June 29, 2026 Yang is New York-based journalist. He spent more than 12 years covering the biotech sector from Beijing as managing editor of Citeline’s Scrip and Pink Sheet. I spent nearly two decades covering the biotech and pharma sector, first in Washington, D.C., and then in Beijing. My first story, published in 2007, covered the U.S. Food and Drug Administration’s decision to open its inaugural overseas office in China, a fast-emerging market I later covered for 12 years.
Open in Who Shared Issue with article?
See all 958 licensed articles (972 Total)